Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?
Brief Communication

Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma?

Niraj Shenoy

Mayo Clinic, 200 1st street SW, Rochester 55902, Minnesota, USA

Correspondence to: Niraj Shenoy, MD. Mayo Clinic, 200 1st street SW, Rochester 55902, Minnesota, USA. Email:

Submitted Mar 28, 2017. Accepted for publication Apr 17, 2017.

doi: 10.21147/j.issn.1000-9604.2017.02.10

Dysregulated pseudo-hypoxia (through its effects on cell survival, angiogenesis, metabolism, invasion) and epigenetic dysregulation [through widespread suppression of tumor suppressor genes involved in cell cycle, apoptosis, adhesion, immune evasion, etc. (1)] are considered to be the two central driving pathogenic features in the progression of clear cell Renal Cell Carcinoma (ccRCC) (2,3). These two features also play a significant role in mediating the chemoresistance of radioresistance of ccRCC. The finding of increased DNA methyltransferase 1 (DNMT1) expression in ccRCC by Li et al. (4) provides one mechanistic reason for the previously reported genome wide aberrant methylation seen in ccRCC, leading to the suppression of various important tumor suppressor genes (3,5). Strikingly, this finding may also establish a link between the driver hypoxia inducible factor (HIF) pathway and aberrant methylation seen in von Hippel-Lindau (VHL) defective ccRCC.

Biallelic VHL gene defects are seen in up to 75% of patients with sporadic ccRCC (6). pVHL, product of the VHL tumor suppressor gene, plays a key role in oxygen sensing by targeting HIF-α for ubiquitination and proteasomal degradation. In the absence of VHL activity, HIF-α is stabilized, translocates to the nucleus, where it combines with the constitutionally expressed HIF-1β to form heterodimers that bind to hypoxia response elements (HREs) in a wide range of gene promoters, leading to a pseudo-hypoxic state (7,8). Interestingly, HIF-1α has been shown to enhance the expression of DNMT1 and DNMT3b in cardiac fibroblasts. The promoter region of DNMT1 and DNMT3a was seen to have well defined HREs (9). Therefore, it is possible that the finding of enhanced expression of DNMT1 in ccRCC is due to the enhanced HIF-α stabilization seen in ccRCC.

This potential link between dysregulated hypoxia signaling and aberrant methylation in ccRCC needs to be further studied with correlative studies on HIF-1α/HIF-2α expression and DNMT1 expression in ccRCC and with HIF-α knockdown impact on DNMT1 expression and genome wide methylation in ccRCC. Establishing a link between the driver HIF pathway and the genome-wide aberrant methylation in ccRCC could have a significant translational impact, as we could then expect HIF modifying treatment strategies to also have a restorative effect on the aberrant epigenetics in ccRCC.




Conflicts of Interest: The authors have no conflicts of interest to declare.


  1. Shenoy N, Vallumsetla N, Zou Y, et al. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol 2015;8:88. [PubMed] DOI:10.1186/s13045-015-0180-y
  2. Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol 2016;27:1685–95. [PubMed] DOI:10.1093/annonc/mdw241
  3. Cancer Genome Atlas Research Network. Compre-hensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43–9. [PubMed] DOI:10.1038/nature12222
  4. Li M, Wang Y, Song Y, et al. Aberrant DNA methyl-transferase 1 expression in clear cell renal cell carcinoma development and progression. Chin J Cancer Res 2014;26:371–81. [PubMed] DOI:10.3978/j.issn.1000-9604.2014.08.03
  5. Hu CY, Mohtat D, Yu Y, et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res 2014;20:4349–60. [PubMed] DOI:10.1158/1078-0432.CCR-14-0494
  6. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC cancer 2005;5:57. [PubMed] DOI:10.1186/1471-2407-5-57
  7. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 2015;15:55–64. [PubMed] DOI:10.1038/nrc3844
  8. Shenoy N, Shrivastava M, Sukrithan V, et al. The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies. J Cancer Ther 2015; 6 :511–21. DOI:10.4236/jct.2015.66055
  9. Watson CJ, Collier P, Tea I, et al. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Hum Mol Genet 2014;23:2176–88. [PubMed] DOI:10.1093/hmg/ddt614
  10. Cite this article as: Shenoy N. Link between dysregulated hypoxia signaling and aberrant methylation in clear cell renal cell carcinoma? Chin J Cancer Res 2017;29(2):166-167. doi: 10.21147/j.issn.1000-9604.2017.02.10